Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.
BACKGROUND
Glioblastoma multiforme (GBM) is an umbrella designation that includes a heterogeneous group of primary brain tumors. Several classification strategies of GBM have been reported, some by clinical course and others by resemblance to cell types either in the adult or during development. From a practical and therapeutic standpoint, classifying GBMs by signal transduction pathway activation and by mutation in pathway member genes may be particularly valuable for the development of targeted therapies.


RESULTS
We performed targeted proteomic analysis of 27 surgical glioma samples to identify patterns of coordinate activation among glioma-relevant signal transduction pathways, then compared these results with integrated analysis of genomic and expression data of 243 GBM samples from The Cancer Genome Atlas (TCGA). In the pattern of signaling, three subclasses of GBM emerge which appear to be associated with predominance of EGFR activation, PDGFR activation, or loss of the RAS regulator NF1. The EGFR signaling class has prominent Notch pathway activation measured by elevated expression of Notch ligands, cleaved Notch receptor, and downstream target Hes1. The PDGF class showed high levels of PDGFB ligand and phosphorylation of PDGFRbeta and NFKB. NF1-loss was associated with lower overall MAPK and PI3K activation and relative overexpression of the mesenchymal marker YKL40. These three signaling classes appear to correspond with distinct transcriptomal subclasses of primary GBM samples from TCGA for which copy number aberration and mutation of EGFR, PDGFRA, and NF1 are signature events.


CONCLUSIONS
Proteomic analysis of GBM samples revealed three patterns of expression and activation of proteins in glioma-relevant signaling pathways. These three classes are comprised of roughly equal numbers showing either EGFR activation associated with amplification and mutation of the receptor, PDGF-pathway activation that is primarily ligand-driven, or loss of NF1 expression. The associated signaling activities correlating with these sentinel alterations provide insight into glioma biology and therapeutic strategies.
Brennan
Cameron
C
Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. cbrennan@mskcc.org
Momota
Hiroyuki
H
Hambardzumyan
Dolores
D
Ozawa
Tatsuya
T
Tandon
Adesh
A
Pedraza
Alicia
A
Holland
Eric
E
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000145:classification* / Q000175:diagnosis*; D066246:ErbB Receptors / Q000378:metabolism; D023281:Genomics; D005909:Glioblastoma / Q000145:classification* / Q000175:diagnosis*; D006801:Humans; D008024:Ligands; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D008954:Models, Biological; D025542:Neurofibromin 1 / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D040901:Proteomics / Q000379:methods; D015398:Signal Transduction
D008024:Ligands; D025542:Neurofibromin 1; D010982:Platelet-Derived Growth Factor; D066246:ErbB Receptors